comparemela.com

Page 2 - Aexon Labs News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Press release titled: NLS Pharmaceutics CEO Issues Letter to Shareholders - Form 6-K -December 29, 2023 at 04:39 pm EST

Zürich, Switzerland, December 29, 2023 - NLS Pharmaceutics Ltd. , a Swiss clinical-stage biopharmaceutical company, focused on the discovery and development of innovative therapies for.

United statesUnited kingdomFrance generalElena thyen pighinAlex zwyerClaudio la bassettiFlorence allouche akninMarianne lambertsonAllouche akninClaudio bassettiAllouch akninEuropean neurological societyOngoing business developmentUniversity of bernPatient programPharmaceutics ltd

NLS Pharmaceutics AG: NLS Pharmaceutics CEO Issues Letter to Shareholders

NLS Pharmaceutics AG: NLS Pharmaceutics CEO Issues Letter to Shareholders
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomFrance generalUnited statesFlorence allouche akninAllouch akninAllouche akninMarianne lambertsonStefan klotterElena thyen pighinClaudio la bassettiClaudio bassettiAlex zwyerResearch societyEuropean neurological societyUniversity of bernAmerican academy of sleep medicine

NLS Pharmaceutics CEO Issues Letter to Shareholders

NLS Pharmaceutics CEO Issues Letter to Shareholders
pr-inside.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pr-inside.com Daily Mail and Mail on Sunday newspapers.

United statesElena thyen pighinAlex zwyerResearch societyAmerican academy of sleep medicineAexon lab dual orexin receptor agonistsNews networkAexon labs incOngoing business developmentPharmaceutics ltdChief executive officerMiddle eastCentral nervous systemAmerican academySleep medicineSleep research society

NLS Pharmaceutics : UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS - Form 6-K -December 06, 2023 at 04:49 pm EST

UNAUDITED INTERIM CONDENSED FINANCIAL STATEMENTS Page .

United statesSilvia panigoneSubhasis royCarlos camozziMarianne lambertsonFelix grisardEric konofalGeorge apostolMaria nayvaltRonald hafnerUs eric konofalAlexander zwyerThomas curatoloAstrid sommerCompany board of directorsCompany annual report on form

NLS Pharmaceutics Acquires Rights to Orexin Agonist Platform

NLS Pharmaceutics entered into an exclusive option agreement with Aexon Labs to develop its dual orexin receptor agonists platform.

Alexander zwyerEric konofalAexon labs incPharmaceutics ltdAexon labKleine levin syndromeAexon labs

vimarsana © 2020. All Rights Reserved.